The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.
Robert Fox, MD, FAAN
Advertisement
Articles by Robert Fox, MD, FAAN
Advertisement
Latest Updated Articles
AAN 2025: Tolebrutinib Shows Promise in Slowing Disability Progression for Secondary Progressive Multiple SclerosisPublished: April 9th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
2
Court Ruling Highlights Risks of Improper Dose Adjustments
3
Celebrating Pharmacists: Pharmacist Care Day in Pittsburgh
4
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
5
